Recently, we have seen many viruses behave abnormally. It is time to study the virosphere and understand viral behavior in ...
The pandemic revealed how social policies affect individual health. But not all things social are directly healthcare related.
The FDA makes inconsistent policy decisions with little regard to data. It feigns incompetence to cover for its conflicting incentives.
While celebrating the Fourth of July and all that it represents, we pondered whether physicians should do more to protect ...
Once again, vaping is at the mercy of regulators. The FDA should first understand the origins of the vaping crisis ...
Legal encroachment into medicine creates an artificial conformity. It has led to landmark legal settlements, but poor quality of care.
We often make false equivalencies when debating gun policy. But one thing is clear: there is an inverse relationship between ...
The recent ruling by the Supreme Court sent the country into a tailspin of outrage. However, the problem is not ...
The Supreme Court clarified the matter of good faith in opioid cases. The ruling will improve the patient-physician relationship and ...
The ONDCP announced an initiative aimed at reducing overdose deaths. But by limiting all of addiction into a metric, we ...
Policy makers believe price transparency will help patients make cost-effective decisions. But patient decisions are made through trust, not cost-savings.
We think disclosing the costs of clinical care will reduce overall costs. In reality, price transparency will increase the cost ...
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read moreDaily Remedy offers the best in healthcare information and healthcare editorial content. We take pride in consistently delivering only the highest quality of insight and analysis to ensure our audience is well-informed about current healthcare topics - beyond the traditional headlines.
Daily Remedy website services, content, and products are for informational purposes only. We do not provide medical advice, diagnosis, or treatment. All rights reserved.
© 2026 Daily Remedy
© 2026 Daily Remedy